Oppenheimer Maintains Outperform on Capricor Therapeutics, Raises Price Target to $43
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Leland Gershell has maintained an 'Outperform' rating on Capricor Therapeutics and raised the price target from $15 to $43.
September 25, 2024 | 12:29 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer has increased its price target for Capricor Therapeutics from $15 to $43, maintaining an 'Outperform' rating. This suggests a strong positive outlook for the company's stock.
The significant increase in the price target from $15 to $43 by a reputable analyst suggests a strong positive sentiment towards Capricor Therapeutics. This is likely to boost investor confidence and drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100